title: [Efficacy of pharmacological inhibition of intestinal saccharases in patients with diabetes mellitus type 2 and/or visceral obesity].
abstract: Inhibitors of intestinal enzymes regulate carbohydrate metabolism reducing glycemic index, glycemic load of food and postprandial glycemia which is a prognostic factor of DM2-related cardiovascular complications and death. This class of drugs was proposed for DM2 treatment in 1970s but still holds perspectives. The article gives a detailed description of the mechanism of action, efficacy and safety of inhibitors of alpha-glucosidase and alpha-amilase in experimental and clinical controlled trials.
authors.forename: A S
authors.initials: AS
authors.lastname: Ametov
authors.forename: L L
authors.initials: LL
authors.lastname: Kamynina
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D038321:Glycemic Index; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007422:Intestines / Q000201:enzymology*; D056128:Obesity, Abdominal / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011379:Prognosis; D043324:beta-Fructofuranosidase / Q000037:antagonists & inhibitors*
chemical_list: D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D043324:beta-Fructofuranosidase